Dr. Jeff Dage

Dr. Jeffrey L. Dage is a Senior Research Professor of Neurology at the Indiana University School of Medicine and a primary member of the Stark Neurosciences Research Institute, with a secondary appointment in Medical and Molecular Genetics. His research is dedicated to advancing precision medicine for neurodegenerative diseases, with a focus on developing blood-based biomarkers that transform how conditions like Alzheimer’s disease are diagnosed and treated.

With more than two decades of experience spanning pharmaceutical research and academic discovery, Dr. Dage has been at the forefront of groundbreaking advances in the field. At Eli Lilly and Company, he pioneered the development of assays to measure phosphorylated tau in blood—a discovery that has revolutionized Alzheimer’s research and is now used worldwide to identify disease pathology and predict cognitive decline.

Today, his laboratory continues to push the science of biomarkers forward, expanding applications to other tau-related disorders such as progressive supranuclear palsy and corticobasal degeneration, as well as to Lewy body diseases and neuroinflammation. Dr. Dage also plays a leading role in national research efforts through the Indiana Alzheimer’s Disease Research Center, the Longitudinal Early Onset Alzheimer’s Disease Study, and the Alzheimer’s Diagnosis in Older Adults with Chronic Conditions Network.

In addition, he serves as Scientific Director of the Biomarker Assay Laboratory within the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) and leads assay development for the Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center. Across all these efforts, his goal remains clear: to deliver tools that enable earlier diagnosis, improved monitoring, and more effective therapies for people living with neurodegenerative disease.